Low-level primary clarithromycin resistance of Helicobacter pylori in Reunion Island - 12/03/25
, Laure Kamus a, e, Benoit Pichard d, Laura Peyret-Moreau d, Olivier Belmonte a, Guillaume Miltgen a, e, f, Christophe Burucoa b, cHighlights |
• | The prevalence of H. pylori seems to be higher in Indian Ocean Islands than in France. |
• | The prevalence of H. pylori resistance to clarithromycin has remained stable since 2014. |
• | Primary resistance of H. pylori to clarithromycin is low in Reunion Island (<15 %). |
• | H. pylori resistance to antibiotics is less prevalent in Indian Ocean Islands. |
• | Empirical treatment using triple therapy could be recommended in Indian Ocean Islands. |
Abstract |
Introduction |
The increasing resistance of Helicobacter pylori to clarithromycin leads to an ongoing adaptation of empirical first-line treatment for H. pylori infections.
Patients and methods |
Prospective study (2022–2023) of 364 patients with no previous treatment for H. pylori infection, addressed for gastroduodenal endoscopy to the University Hospital of Reunion Island.
Results |
PCR tests (AllplexTM H. pylori & ClariRAssay, Seegene) performed on gastric biopsy samples detected H. pylori DNA in 100 samples (100/364; 27.5 %) and mutations conferring resistance to clarithromycin in 10 of the positive samples (10/100; 10 %). Prevalence of resistance determined by MICs (E-test method) was 41.2 % for metronidazole, 13.2 % for levofloxacin, 8.8 % for clarithromycin. No resistance was detected for tetracycline, rifampicin, and amoxicillin.
Conclusion |
The prevalence of primary clarithromycin-resistant H. pylori in Reunion Island is below 15 %. Recommendation for the standard clarithromycin-based triple therapy as a first-line treatment can thus be maintained, even though antimicrobial susceptibility testing seems preferable.
Le texte complet de cet article est disponible en PDF.Keywords : Helicobacter pylori, Antimicrobial susceptibility, Clarithromycin, Therapeutic regimens, Reunion Island
Plan
Vol 55 - N° 2
Article 105025- mars 2025 Retour au numéro
Article précédent
- Clinical, biological, metabolic, and immune changes associated with the use of sodium-glucose cotransporter 2 inhibitors in people living with HIV
- Vincent Guiraud, Delphine Sauce, Randa Bittar, José Fernandez, Henri Thévenet, Elisa Teyssou, Rana Alkouri, Dominique Bonnefont-Rousselot, Anne-Geneviève Marcelin, Vincent Calvez, Valérie Pourcher
- Impact of an antimicrobial stewardship program on the appropriate use of carbapenems in a French university hospital (CARBACAI study)
- Julia Santucci, Guillaume Saint-Lorant, Aurélie Baldolli, Christophe Isnard, Pascal Thibon, Arnaud de La Blanchardiere
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?